SEC Filing | Cytokinetics, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Sabry James H

(Last)

(First)

(Middle)

52 BUENA VISTA TERRACE

(Street)

SAN FRANCISCO

94117

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/28/2004

3. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
President & CEO

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	250,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Employee Stock Option (right to buy)	09/28/1999⁽¹⁾	09/28/2009	Common Stock	62,500⁽²⁾	0.29	D
Employee Stock Option (right to buy)	11/14/2000⁽¹⁾	11/14/2010	Common Stock	250,000⁽³⁾	0.29	D
Employee Stock Option (right to buy)	07/10/2002⁽¹⁾	07/10/2012	Common Stock	300,000⁽⁴⁾	0.6	D
Employee Stock Option (right to buy)	05/21/2003⁽¹⁾	05/21/2013	Common Stock	75,000⁽⁵⁾	0.6	D
Employee Stock Option (right to buy)	03/08/2004⁽¹⁾	03/08/2014	Common Stock	86,500⁽⁶⁾	3.25	D

Explanation of Responses:

1. The shares subject to the Option are immediately exercisable upon the Date of Grant.

2. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/4th after one year (May 1, 1999) and 1/48th per month thereafter

3. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/60th after one month (December 14, 2000) and 1/60th per month thereafter.

4. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/60th after one month (April 15, 2002) and 1/60th per month thereafter.

5. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/48th after one month (April 1, 2003) and 1/48th per month thereafter.

6. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/48th after one month (April 8, 2004) and 1/48th per month thereafter.

	/s/ James H. Sabry	04/28/2004
	/s/ Robert I. Blum, by power of attorney	04/28/2004
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.




                                POWER OF ATTORNEY

         The undersigned, as a Section 16 reporting person of Cytokinetics,
Incorporated (the "Company"), hereby constitutes and appoints Robert I. Blum,
the undersigned's true and lawful attorney-in-fact to:

         1.       complete and execute Forms 3, 4 and 5 and other forms and all
                  amendments thereto as such attorney-in-fact shall in his or
                  her discretion determine to be required or advisable pursuant
                  to Section 16 of the Securities Exchange Act of 1934 (as
                  amended) and the rules and regulations promulgated thereunder,
                  or any successor laws and regulations, as a consequence of the
                  undersigned's ownership, acquisition or disposition of
                  securities of the Company; and

         2.       do all acts necessary in order to file such forms with the
                  Securities and Exchange Commission, any securities exchange or
                  national association, the Company and such other person or
                  agency as the attorney-in-fact shall deem appropriate.

         The undersigned hereby ratifies and confirms all that said
attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934 (as amended).

         This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
Company and the foregoing attorneys-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 23rd day of April, 2004.



                             Signature: /s/ James H. Sabry
                                        ----------------------------------------

                             Print Name: James H. Sabry
                                         ---------------------------------------